Improving Tumor Oxygenation in Cervical Cancer
Information source: University of California, Irvine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cervical Cancer
Intervention: Methazolamide (Drug); Cisplatin (Drug)
Phase: Phase 2
Status: Withdrawn
Sponsored by: University of California, Irvine Official(s) and/or principal investigator(s): Devansu Tewari, MD, Principal Investigator, Affiliation: Chao Family Comprehensive Cancer Center
Summary
The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with
ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are
affected adversely by acidic pH. These effects have primarily been attributed to the
presence of hypoxic cells within the tumor. The relevance of hypoxia with respect to
failure of radiotherapy to cure certain malignancies has had a chequered history. However,
in recent years the evidence that hypoxia plays a central role in relative radioresistance
has become more compelling.
Since approximately two-thirds of all women suffering from cervical carcinoma receive
radiation as a component of their therapy, an enhanced understanding of the interactions
between hypoxia and radiation as a component of their therapy, an enhanced understanding of
the interactions between hypoxia and radiation resistance is critical to improving outcome
among those with cervical cancer.
Clinical Details
Official title: Improving Tumor Oxygenation in Cervical Cancer With Methazolamide
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To assess the feasibility in improving tumor oxygenation
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- The subject will have a malignant tumor of the cervix which is not curable by surgery
in which it has been determined the subject is to receive the standard care of
treatment of radiation therapy and chemotherapy.
- The subject must have adequate bone marrow function, renal function, hepatic function
and neurologic function.
- The subject should be free of active infection requiring antibiotics.
- The subject must have signed the approved informed consent
- If the subject is of childbearing age, they must have a negative urine pregnancy test
with effective contraception
- The subject must have met pre-entry requirements
1. Physical examination to include pelvic examination, blood counts, assessment of
liver and kidney status through blood studies
2. A serum pregnancy test
3. Detectable tumor will be measured.
Exclusion Criteria:
- The subject has not been clinically staged for their cancer
- The subject has evidence of or is being treated for an active infection
- The subject cannot perform the appropriate follow-up or complete the study for
whatever reason.
- The subject has not consented to an additional tumor biopsy and MRI after my seven
days of treatment with methazolamide
- The subject has evidence of chronic obstructive pulmonary disease
- The subject is currently breastfeeding
- The subject is pregnant
- The subject takes aspirin chronically
- The subject has a history of Stevens-Johnson syndrome
- The subject has not signed the approved informed consent
Locations and Contacts
Additional Information
Starting date: July 2004
Last updated: February 27, 2008
|